HCAT vs INTC Stock Comparison
Compare HCAT and INTC across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between HCAT and INTC?
HCAT leads the current stock comparison as Health Catalyst, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Health Catalyst, Inc. vs Intel Corp.
HCAT leads
HCAT leads by 5 AIQ points, primarily on Value and Risk Resilience.
Competitive: 5 of 6 evidence groups support HCAT, and its signal state is cleanly positive.
Health Catalyst, Inc.
Intel Corp.
The Algovestiq AIQ Score currently favors HCAT over INTC, 49 versus 44 as of Sep 11, 2026. HCAT's advantage is driven primarily by stronger value and risk resilience, while INTC holds the stronger momentum profile. HCAT also shows the weaker technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor HCAT today, and the comparison is rated Competitive on stability: the AIQ gap is narrow at 5 points. HCAT lead: Stable — the AIQ differential has held near 5 points over 30 sessions.
Compare Health Catalyst, Inc. and Intel Corp. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare HCAT and INTC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value73 vs 30HCAT +43
- Momentum52 vs 77INTC +25
- Quality26 vs 39INTC +13
- Risk Resilience39 vs 28HCAT +11
5 of 6 evidence groups favor HCAT. HCAT’s edge is concentrated in value and risk resilience; INTC keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +7
No new signals fired.
Largest factor move: Momentum -8
New signals
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
HCAT's lead widened by 4 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — HCAT and INTC both carry a full feed there.
The central trade-off
HCAT (Health Catalyst, Inc.): the stronger current systematic profile, led by value and risk resilience.
INTC (Intel Corp.): the counter-case, on momentum, quality, technicals — but at materially higher volatility, 58.9% against 52.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
HCATHCAT on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
HCATHCAT on combined revenue and EPS growth.
Value
HCATHCAT on the peer-relative Value factor, by 43 points.
Momentum
INTCINTC on the Momentum factor, by 25 points.
Lower downside
HCATHCAT on Risk Resilience, by 11 points.
Analyst upside
HCATHCAT on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | HCAT | INTC | Note |
|---|---|---|---|
| Implied upside to target | +22.4% | -0.1% | HCAT has more room |
| Target dispersion | +60.1% | +136.1% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 3 | 27 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor HCAT. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | HCAT | 49 vs 44 |
| Fundamentals | HCATon balance | EPS growth 64.1% vs -195.9%; TTM ROE -129.7% vs -10.8%; gross margin 46.4% vs 38.9% — HCAT takes 2 of 3 decided legs, not all of them |
| Valuation | HCAT | Value 73 vs 30 |
| Technicals | INTC | Price vs 50-day -12.8% vs 4.2%; vs 200-day -6.6% vs 33.4% |
| Risk Resilience | HCAT | Risk Resilience 39 vs 28 |
| Analyst expectations | HCAT | Target upside 22.4% vs -0.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of HCAT and INTC and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on HCAT.
How the comparison changed
119 daily snapshots · May 4 – Sep 10HCAT lead: Stable — the AIQ differential has held near 5 points over 30 sessions.
- Today
- HCAT +5
- 49 vs 44
- 7 sessions ago
- HCAT +11
- 46 vs 35
- 30 sessions ago
- HCAT +5
- 43 vs 38
- 90 sessions ago
- HCAT +22
- 55 vs 33
The lead changed hands once in this window, most recently on May 14 when INTC moved ahead of HCAT.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (5.20%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.40%)
- MACD Bullish Crossover — bullish, momentum, short horizon
4 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (31.44%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -1.73%, AIQ +2 points).
Price is up while the AIQ Score moved down 2 points over the same session — price and model disagree (price +2.61%, AIQ -2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1INTC closes the Value gap — currently 43 points behind, the largest single contributor to HCAT's edge.
- 2INTC's existing bullish trend signals translate into factor-score gains — the rules are already firing, but the scores have not yet followed.
- 3HCAT's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
HCAT leads on balance| Metric | HCAT | INTC |
|---|---|---|
| Revenue growth (YoY) | -0.4% | 18.8% |
| EPS growth (YoY) | 64.1% | -195.9% |
| Gross margin | 46.4% | 38.9% |
| Operating margin | -19.7% | 0.1% |
| Return on equity (TTM) | -129.7% | -10.8% |
| Debt to equity | 1.69 | 0.58 |
Performance
INTC leads 5 of 6 windows| Metric | HCAT | INTC |
|---|---|---|
| 1 week (5 sessions) | 2.4% | 11.4% |
| 1 month (20 sessions) | -3.4% | -0.6% |
| 3 months (63 sessions) | 8.1% | -6.3% |
| 6 months (126 sessions) | -7% | 109.1% |
| Year to date | -27.6% | 171.9% |
| 1 year (252 sessions) | -48.8% | 309.8% |
Technicals
INTC has the stronger structure| Metric | HCAT | INTC |
|---|---|---|
| RSI (14) | 62.5 | 61.3 |
| ADX (14) | 18.8 | 15.5 |
| Price vs 50-day | -12.8% | 4.2% |
| Price vs 200-day | -6.6% | 33.4% |
| Volatility (1M, annualized) | 52.4% | 58.9% |
Risk
HCAT is the more resilient| Metric | HCAT | INTC |
|---|---|---|
| Beta | 1.34 | 2.89 |
| Sharpe ratio | -0.36 | 2.12 |
| Sortino ratio | -0.57 | 3.98 |
| Max drawdown | -70.7% | -41.9% |
| Current drawdown | -49.1% | -28.8% |
| Annualized volatility | 90% | 79.9% |
| Value at risk (95%) | -6.9% | -6.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, HCAT or INTC?
On the Algovestiq AIQ Score, HCAT is the stronger of the two as of Sep 11, 2026, scoring 49 against INTC's 44. The edge comes from value and risk resilience. INTC is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is HCAT or INTC the better buy right now?
HCAT carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 5 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor HCAT over INTC?
The composite weights Quality, Value, Momentum and Risk Resilience. HCAT leads Value by 43 points; INTC leads Momentum by 25 points; INTC leads Quality by 13 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, HCAT or INTC?
Analyst price targets imply +22.4% upside for HCAT and -0.1% for INTC, so the Street currently favors HCAT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, HCAT or INTC?
HCAT is the better-valued of the two on the peer-relative Value factor. HCAT on the peer-relative Value factor, by 43 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, HCAT or INTC?
HCAT on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, HCAT or INTC?
INTC on the Momentum factor, by 25 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, HCAT or INTC?
HCAT is the more resilient of the two, so the other name carries the higher downside risk. HCAT on Risk Resilience, by 11 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is HCAT more profitable than INTC?
The profitability evidence is mixed: gross margin 46.4% vs 38.9%; operating margin -19.7% vs 0.1%; ttm roe -129.7% vs -10.8%. Each name leads on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is HCAT's lead over INTC getting stronger or weaker?
HCAT lead: Stable — the AIQ differential has held near 5 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands once in that window, most recently on 2026-05-14, when INTC moved ahead of HCAT.
What would change the HCAT vs INTC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: INTC closes the Value gap — currently 43 points behind, the largest single contributor to HCAT's edge; INTC's existing bullish trend signals translate into factor-score gains — the rules are already firing, but the scores have not yet followed; HCAT's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about HCAT and INTC?
HCAT: 2 bullish / 0 bearish / 1 neutral. INTC: 4 bullish / 0 bearish / 1 neutral. The most decision-relevant rule on HCAT is Golden Cross Active (bullish, long horizon). On INTC it is Golden Cross Active (bullish, long horizon).
Compare HCAT and INTC with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.